EGFR and lung adenocarcinoma: In Category I-1 (n = 28; Supplementary Table 1), 15 patients harbored actionable point mutations, such as EGFR L858R in lung adenocarcinomas (actionable with erlotinib and others)33, BRAF V600E in colon cancers (actionable with encorafenib)34, PIK3CA H1047R/N345K in hormone positive breast cancers (actionable with alpelisib)35, and FGFR3 G370C/S249C/Y737C in urothelial cancers (actionable with erdafitinib)36.